Contrast-induced nephropathy in outpatients with preexisting renal impairment: a comparison between intravenous iohexol and iodixanol

Clin Imaging. 2016 Sep-Oct;40(5):902-6. doi: 10.1016/j.clinimag.2016.04.008. Epub 2016 Apr 26.

Abstract

Background: Concern for contrast-induced nephropathy (CIN) may result in administration of more costly agents. We prospectively compared outpatient CIN incidence of iodixanol to iohexol.

Methods: Patients were randomized to receive 100ml of iohexol (n=47) or iodixanol (n=55). We compared patients who developed CIN using the Wilson score interval and also calculated an odds ratio for the development of CIN.

Results: CIN rate for iohexol was 2% compared to 9% for iodixanol. Those receiving iodixanol were almost 5 times more likely to experience CIN.

Conclusion: These results do not suggest a benefit of iodixanol over iohexol in the study population.

Keywords: Contrast nephropathy (CIN); Iodixanol; Iohexol; Outpatient.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / diagnosis
  • Acute Kidney Injury / epidemiology
  • Adult
  • Aged
  • Aged, 80 and over
  • Contrast Media / administration & dosage
  • Contrast Media / adverse effects
  • Dose-Response Relationship, Drug
  • Female
  • Florida / epidemiology
  • Humans
  • Incidence
  • Injections, Intravenous
  • Iohexol / administration & dosage
  • Iohexol / adverse effects*
  • Male
  • Middle Aged
  • Outpatients*
  • Prognosis
  • Renal Insufficiency / complications
  • Renal Insufficiency / diagnosis*
  • Renal Insufficiency / epidemiology
  • Tomography, X-Ray Computed / adverse effects*
  • Tomography, X-Ray Computed / methods
  • Triiodobenzoic Acids / administration & dosage
  • Triiodobenzoic Acids / adverse effects*

Substances

  • Contrast Media
  • Triiodobenzoic Acids
  • Iohexol
  • iodixanol